Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN versus POHERDY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN versus POHERDY.
CORDRAN vs POHERDY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
POHERDY is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), binding to domain IV of the extracellular segment, thereby inhibiting ligand-independent HER2 signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).
Apply a thin layer to the affected skin areas once or twice daily. For CORDRAN Tape, apply tape to affected area once every 12 to 24 hours.
POHERDY: No approved drug. No dosing available.
None Documented
None Documented
Terminal half-life is approximately 7.5 hours (range 6-10 hours) in adults with normal hepatic function. This supports twined-daily dosing for dermatological indications.
Terminal half-life 12–18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min)
Primarily hepatic metabolism; metabolites excreted in urine and feces. Renal excretion of unchanged drug is negligible (<5%). Biliary/fecal excretion accounts for ~20% of metabolites.
Renal: 60% unchanged; fecal/biliary: 30%; 10% metabolized
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid